## **IRB Protocol Review Standards**

Minimal regulatory requirements for IRB review, discussion and documentation in the meeting minutes

Regulatory review requirement	Suggested questions for IRB discussion
YESNO  1. The proposed research design is scientifically sound & will not unnecessarily expose subjects to risk.	(a) Is the hypothesis clear? Is it clearly stated?  (b) Is the study design appropriate to prove the hypothesis?  (c) Will the research contribute to generalizable knowledge and is it worth exposing subjects to risk?
YESNO  2. Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of knowledge that may reasonably be expected to result.	(a) What does the IRB consider the level of risk to be? (See risk assessment guide on the next page.)  (b) What does the PI consider the level of risk/discomfort/ inconvenience to be?  (c) Is there prospect of direct benefit to subjects? (See benefit assessment guide on the next page.)
YESNO  3. Risks to subjects are minimized.	(a) Does the research design minimize risks to subjects?  (b) Would use of a data & safety monitoring board or other research oversight process enhance subject safety?

YESNO  4. Subject selection is equitable.	(a) Who is to be enrolled? Men? Women? Ethnic minorities? Children (rationale for inclusion/exclusion addressed)? Seriously-ill persons? Healthy volunteers?  (b) Are these subjects appropriate for the protocol?
YESNO  5. Informed consent is obtained from research subjects or their legally authorized representative(s).	(a) Does the informed consent document include the eight required elements?
	(b) Is the consent document understandable to subjects?
	(c) Who will obtain informed consent (PI, nurse, other?) & in what setting?
	(d) If appropriate, is there a children's assent?
	(e) Is the IRB requested to waive or alter any informed consent requirement?
YESNO  6. Additional safeguards required for subjects likely to be vulnerable to coercion or undue	(a) Are appropriate protections in place for vulnerable subjects, e.g., pregnant women, fetuses, socially- or economically-disadvantaged, decisionally-impaired?
influence. YESNO  7. Subject privacy & confidentiality are maximized.	(a) Will personally-identifiable research data be protected to the extent possible from access or use?
	(b) Are any special privacy & confidentiality issues properly addressed, e.g., use of genetic information?

YESNO  1. Ionizing radiation.	If ionizing radiation is used in this protocol is it medically indicated or for research use only?
YESNO  2. Collaborative research.	Is this domestic/international collaborative research? If so, are SPAs or other assurances required for the sites involved?
YESNO	Is an IND or IDE involved in this protocol?
3. FDA-regulated research	
YESNO	Other comments/questions/concerns?
4. Other	